



INVESTORS TO HEAR FROM BIOCRYST PHARMACEUTICALS, INC. AT THE BIOTECH/PHASE III DRUG STOCKS FORUM ON APRIL 3

Charles E. Bugg, Ph.D., Chairman and Chief Executive Officer, to Present

Richmond, VA – March 28, 2003 – Investors interested in biotech and phase III drug companies and their investment value can gather insights as BioCryst Pharmaceuticals, Inc. (NasdaqNM: BCRX) presents at Informed Investors' forum on Thursday, April 3 at 9:30 a.m. EST.

This free online Forum gives investors the opportunity to hear directly from BioCryst and other biotech company executives. The presentation will be accessible live at www.informedinvestors.com beginning at 9:00 a.m. EST. As part of the forum, Investors are invited to email questions to the executives. The forum will also be archived and available afterwards on www.informedinvestors.com and www.vcall.com.

Charles E. Bugg, Ph.D., a co-founder of BioCryst Pharmaceuticals, has pioneered numerous advances in the fields of X-ray crystallography and structure-based drug design. Previously, he was Director of the Center for Macromolecular Crystallography, Associate Director of the Comprehensive Cancer Center and Professor of Biochemistry at The University of Alabama at Birmingham. In 26 years at UAB, Dr. Bugg led research to characterize the structure of human interferon gamma, played a leading role in the groundbreaking crystallography research that formed the foundation of BioCryst's drug development program. He was honored with the Milstein Award in 1994 for his research on human interferon gamma.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel drugs that block key enzymes essential for cancer, cardiovascular diseases and viral infections. BioCryst integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer modeling to effectively use structure-based drug design to discover and develop small molecule pharmaceuticals. Enrollment in a Phase I/II trial for one of BioCryst's product candidates, BCX-1777, is underway at the M.D. Anderson Cancer Center for patients with T-cell leukemias and T-cell lymphomas. BioCryst has several new enzyme targets in drug discovery including tissue factor/factor VIIa, hepatitis C polymerase and complement component C1s. For more information about BioCryst, please visit the company's web site at www.biocryst.com.

Informed Investors is the leading producer of online and offline industry-specific investment conferences for investors and a member of the WILink suite of PrecisionIR™ services serving publicly traded companies and self-directed investors. Companies wanting to participate in the forum should contact Tracy Jones at tjones@wilink.com.

About WILink

Since 1992, WILink plc (www.wilink.com) has been a leading provider of global investor relations and investment information services that attract and retain investors for public companies and mutual funds. WILink's PrecisionIR™ (www.precisionir.com) and PrecisionFM™ custom investment marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year WILink will make more than 8 million investor introductions for over 3,750 corporate clients through PrecisionIR™ and PrecisionFM™ programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com), Vcall® webcasting (www.vcall.com), InstitutionalReach™ and PeerEvents. WILink's partnerships with over 240 leading financial channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance ensure clients targeted visibility within the investment community. WILink, Inc. a wholly owned subsidiary of WILink plc (WLK: LSE) began operations in Richmond, Va. in 1993.